The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 18, 2023

Filed:

May. 17, 2021
Applicant:

Avixgen Inc., Seoul, KR;

Inventors:

Young Myeong Kim, Gangwon-do, KR;

Yi Yong Baek, Gyeonggi-do, KR;

Won Jin Park, Gyeonggi-do, KR;

Jeong Hun Kim, Seoul, KR;

Dong Hyun Jo, Seoul, KR;

Assignee:

AVIXGEN INC., Seoul, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 5/11 (2006.01); A61K 38/07 (2006.01); A61P 27/02 (2006.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 5/1019 (2013.01); A61P 27/02 (2018.01); A61P 35/00 (2018.01); A61K 38/00 (2013.01);
Abstract

Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.


Find Patent Forward Citations

Loading…